Merck & co., inc.MRK.US Overview
MRK Overall Performance
MRK AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
MRK Current Performance
1.09%
Merck & co., inc.
-0.47%
Avg of Sector
-0.64%
S&P500
MRK Key Information
MRK Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
MRK Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
MRK Profile
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Price of MRK
MRK FAQ
When is MRK's latest earnings report released?
The most recent financial report for Merck & co., inc. (MRK) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MRK's short-term business performance and financial health. For the latest updates on MRK's earnings releases, visit this page regularly.
Where does MRK fall in the P/E River chart?
According to historical valuation range analysis, Merck & co., inc. (MRK)'s current price-to-earnings (P/E) ratio is 12.3, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of MRK?
According to the latest financial report, Merck & co., inc. (MRK) reported an Operating Profit of 4.99B with an Operating Margin of 31.58% this period, representing a decline of 17.46% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is MRK's revenue growth?
In the latest financial report, Merck & co., inc. (MRK) announced revenue of 15.81B, with a Year-Over-Year growth rate of -1.9%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does MRK have?
As of the end of the reporting period, Merck & co., inc. (MRK) had total debt of 35.4B, with a debt ratio of 0.3. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does MRK have?
At the end of the period, Merck & co., inc. (MRK) held Total Cash and Cash Equivalents of 8.01B, accounting for 0.07 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does MRK go with three margins increasing?
In the latest report, Merck & co., inc. (MRK) achieved the “three margins increasing” benchmark, with a gross margin of 77.5%%, operating margin of 31.58%%, and net margin of 28%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess MRK's profit trajectory and future growth potential.
Is MRK's EPS continuing to grow?
According to the past four quarterly reports, Merck & co., inc. (MRK)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 1.76. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of MRK?
Merck & co., inc. (MRK)'s Free Cash Flow (FCF) for the period is 2.53B, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 47.81% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of MRK?
The latest valuation data shows Merck & co., inc. (MRK) has a Price-To-Earnings (PE) ratio of 12.3 and a Price/Earnings-To-Growth (PEG) ratio of -0.9. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.